sinc
two
human
coronavirus
sarscov
merscov
emerg
global
public
health
threat
sarscov
first
identifi
februari
guangdong
provinc
peopl
republ
china
transmit
human
infect
civet
like
infect
bat
sarscov
spread
addit
countri
associ
high
morbid
human
eg
atyp
pneumonia
ultim
sar
contain
follow
highli
effect
public
health
respons
result
confirm
case
death
fig
mer
emerg
kingdom
saudi
arabia
present
sever
respiratori
diseas
frequent
gastrointestin
renal
complic
merscov
caus
agent
mer
later
identifi
coronaviru
merscov
subsequ
spread
addit
countri
fig
septemb
confirm
case
mer
death
report
coronavirus
envelop
singlestrand
positivesens
rna
virus
fig
member
coronavirina
subfamili
virus
togeth
torovirina
subfamili
compris
coronavirida
viru
famili
order
nidoviral
coronavirina
divid
four
genera
alpha
coronaviru
beta
coronaviru
gamma
coronaviru
delta
coronaviru
coronavirus
share
similar
genom
organ
open
read
frame
compris
nearli
genom
encod
nonstructur
protein
multipl
structur
protein
includ
spike
nucleocapsid
envelop
membran
protein
encod
downstream
open
read
frame
fig
sarscov
merscov
belong
beta
coronaviru
genu
howev
sarscov
belong
lineag
b
merscov
belong
lineag
c
along
bat
coronavirus
merscov
bat
coronavirus
part
lineag
c
merscov
rna
found
bat
sampl
kingdom
saudi
arabia
research
hypothes
bat
may
natur
reservoir
merscov
result
recent
studi
support
bat
may
reservoir
merscov
howev
camel
goat
thought
intermedi
host
studi
merscov
isol
nasal
secret
merscovinfect
dromedari
camel
short
mild
diseas
progress
suspect
reservoir
sarscov
chines
horsesho
bat
howev
mechan
emerg
adapt
make
viru
zoonot
still
definit
understood
sarscovlik
isol
bat
sequenc
similar
human
civet
sarscov
initi
outbreak
sarscov
origin
isol
palm
civet
found
chines
market
sarscov
found
wild
palm
civet
popul
bat
harbor
mani
coronavirus
consid
main
reservoir
later
infect
intermedi
host
civet
camel
spread
diseas
human
humantohuman
transmiss
commonli
associ
healthcar
worker
close
unprotect
contact
infect
patient
clinic
featur
mer
sar
similar
rang
asymptomat
mild
diseas
sever
pneumonia
acut
respiratori
distress
syndrom
ard
multiorgan
failur
although
mer
sar
clinic
similar
mer
mortal
rate
sar
mortal
rate
approxim
mer
case
associ
underli
comorbid
mortal
rate
subgroup
includ
cardiopulmonari
abnorm
obes
diabet
contrast
patient
sar
comorbid
mortal
rate
within
subgroup
develop
symptomat
mer
sar
mostli
occur
adult
median
age
year
year
sar
mer
sar
symptom
typic
follow
mean
incub
time
day
rang
day
respect
includ
fever
chill
cough
associ
blood
short
breath
myalgia
headach
nausea
vomit
diarrhea
sore
throat
malais
progress
mild
sever
diseas
rapid
mer
compar
sar
mean
day
respect
secondari
bacteri
infect
occur
patient
sever
mer
howev
role
coinfect
mer
pathogenesi
yet
determin
laboratori
abnorm
associ
mer
sar
patient
includ
elev
lactat
dehydrogenas
elev
liver
enzym
thrombocytopenia
lymphopenia
leukopenia
radiograph
abnorm
consist
viral
pneumon
ard
common
mer
sar
radiograph
progress
lower
lobe
report
rapid
mer
sar
sar
diseas
lower
lobe
mimic
pneumonia
radiograph
progress
includ
groundglass
opacif
lobe
thicken
merscov
intact
viru
viral
genom
found
higher
concentr
lower
respiratori
tract
upper
respiratori
tract
mer
patient
may
account
ineffici
interhuman
transmiss
current
approv
therapeut
patient
mer
sar
avail
clinic
manag
reli
primarili
support
care
effect
antivir
treatment
use
sar
epidem
mainli
base
case
studi
retrospect
analysi
patient
cohort
random
blind
clinic
trial
antisar
treatment
perform
add
complex
interpret
avail
data
tabl
ribavirin
nucleosid
analog
prevent
rna
dna
viru
replic
initi
use
treatment
sar
due
broadspectrum
efficaci
exampl
taiwanes
studi
sar
patient
treat
daili
fluoroquinolon
antibiot
levofloxacin
mg
moxifloxacin
mg
follow
diagnosi
patient
sar
patient
also
treat
intraven
iv
mg
ribavirin
oral
daili
mg
sar
patient
receiv
ribavirin
corticosteroid
iv
methylprednisolon
oral
prednisolon
administ
need
treat
worsen
lung
infiltr
fever
ribavirin
treatment
led
hypoxia
anemia
increas
risk
death
sar
patient
retrospect
analysi
cohort
patient
hong
kong
singapor
toronto
treat
ribavirin
conjunct
corticosteroid
immunoglobulin
andor
antibiot
ribavirin
demonstr
efficaci
patient
hong
kong
singapor
treat
ribavirin
mg
oral
diagnosi
follow
oral
treatment
mg
daili
continu
iv
ribavirin
therapi
mgkg
everi
h
h
toronto
patient
receiv
ribavirin
iv
treatment
mg
follow
mg
everi
h
day
mg
everi
h
day
unfortun
fatal
rate
similar
ribavirintr
control
group
later
research
demonstr
ribavirin
dosag
requir
effect
sarscov
vitro
clinic
achiev
ribavirin
treatment
also
result
advers
effect
includ
anemia
hypoxemia
decreas
hemoglobin
level
improv
patient
outcom
due
increas
advers
effect
lack
efficaci
health
canada
stop
permit
use
ribavirin
sar
addit
studi
test
efficaci
ribavirin
conjunct
lopinavir
antiretrovir
agent
lopinavir
demonstr
vitro
activ
sarscov
nonrandom
openenrol
trial
suspect
sar
patient
patient
treat
ribavirin
corticosteroid
similar
previous
describ
studi
addit
confirm
sar
patient
also
treat
combin
lopinavir
mg
ritonavir
mg
mean
viral
load
nasopharyng
swab
within
treatment
group
decreas
undetect
level
day
overal
sarsrel
symptom
subsid
diseas
progress
milder
advers
effect
report
compar
histor
control
group
openlabel
nonrandom
studi
sar
patient
patient
receiv
subcutan
sc
inject
interferon
ifn
day
initi
dose
day
increas
diseas
progress
patient
surviv
minor
advers
effect
evalu
treatment
mer
patient
hamper
highqual
clinic
data
random
clinic
trial
limit
ribavirin
without
ifn
corticosteroid
primari
treatment
mer
outbreak
retrospect
analysi
cohort
patient
treat
oral
ribavirin
sc
pegyl
dose
week
tabl
initi
dose
ribavirin
mg
follow
mg
dose
depend
creatinin
clearanc
group
patient
receiv
support
care
corticosteroid
consid
control
group
day
confirm
diagnosi
mer
surviv
increas
treat
group
compar
control
group
day
postdiagnosi
treat
subject
surviv
versu
control
group
addit
case
studi
greek
patient
contract
mer
jeddah
treat
oral
lopinavirritonavir
mg
twice
daili
pegyl
ifn
sc
per
week
week
ribavirin
mg
initi
dose
mg
everi
h
day
initi
day
postdiagnosi
two
day
treatment
initi
viremia
could
detect
howev
viral
rna
detect
sever
patient
sampl
fece
respiratori
secret
serum
week
postdiagnosi
despit
prolong
surviv
patient
succumb
septic
shock
month
postdiagnosi
ongo
random
clinic
trial
saudi
arabia
evalu
treatment
mer
patient
combin
lopinavirritonavir
loperamid
approv
antidiarrh
agent
world
health
organ
model
list
essenti
medicin
avail
mani
countri
drug
act
opioid
receptor
reduc
intestin
motil
result
pharmacokinet
pk
studi
show
oral
loperamid
well
absorb
gut
less
drug
enter
system
circul
loperamid
demonstr
antimerscov
antisar
activ
vitro
screen
approv
drug
although
mechan
action
unknown
interestingli
loperamid
suggest
limit
gastrointestin
fluid
electrolyt
loss
patient
ebola
viru
diseas
evd
antimalari
agent
chloroquin
cq
amodiaquin
mefloquin
activ
sarscov
merscov
vitro
cq
us
food
drug
administr
fda
approv
antimalari
agent
also
use
treat
autoimmun
diseas
rheumatoid
arthriti
due
antiinflammatori
effect
cq
activ
number
virus
vitro
vivo
includ
flavivirus
dengu
viru
denv
togavirus
chikungunya
viru
chikv
paramyxovirus
hendra
nipah
viru
influenza
virus
hiv
filovirus
ebola
viru
ebov
sever
mechan
action
identifi
antivir
effect
cq
suggest
drug
act
nonspecif
viru
entri
later
stage
viru
product
cq
accumul
within
acid
organel
endosom
golgi
vesicl
lysosom
drug
proton
result
increas
ph
within
vesicl
virus
depend
acid
organel
entri
viral
replic
matur
viru
progeni
similarli
merscov
entri
cell
depend
sever
proteas
dipeptidyl
peptidas
act
function
viru
receptor
cellular
proteas
eg
type
ii
transmembran
serin
proteas
member
cathepsin
famili
activ
viral
spike
glycoprotein
cq
may
effect
proteas
cq
also
affect
glycosyl
step
within
golgi
direct
traffick
matur
viral
protein
sarscov
antivir
activ
cq
also
attribut
deficit
glycosyl
receptor
angiotensinconvert
enzym
broadspectrum
antivir
activ
make
cq
attract
antivir
repurpos
treat
coronavir
emerg
viral
infect
vivo
activ
cq
mer
sar
anim
model
yet
report
howev
antivir
activ
drug
evalu
virus
preclin
clinic
studi
mix
result
cq
plasma
steadi
state
concentr
mice
similar
report
human
within
rang
valu
determin
merscov
sarscov
preclin
studi
cq
mice
virus
shown
surviv
benefit
influenza
ebov
infect
clinic
studi
cq
effect
reduc
viral
load
asymptomat
hiv
patient
result
cq
treatment
chikv
denv
infect
mix
summari
cq
broadspectrum
potenti
inform
gain
studi
virus
use
plan
appropri
strategi
evalu
specif
clinic
valu
treat
merscov
sarscov
infect
cq
sever
advantag
includ
rapid
absorpt
gastrointestin
tract
low
cost
effect
biodistribut
cq
may
excel
candid
combinatori
treatment
antivir
howev
consider
challeng
remain
treatment
viral
infect
includ
increas
understand
pharmacodynam
cq
achiev
suffici
plasma
concentr
patient
toxic
concern
importantli
hydroxychloroquin
cq
deriv
may
provid
altern
due
lower
toxic
similar
pharmacolog
profil
relat
antimalari
drug
amodiaquin
also
activ
vitro
merscov
sarscov
previou
investig
demonstr
amodiaquin
inhibit
filoviru
replic
mechan
action
hypothes
similar
cq
amodiaquin
well
toler
commonli
use
malaria
treatment
mani
countri
amodiaquin
combin
artesun
administ
evd
patient
epidem
result
decreas
fatal
rate
may
associ
use
amodiaquin
antimalari
agent
nonhuman
primat
nhp
studi
current
underway
investig
effect
amodiaquin
treatment
evd
mefloquin
synthet
analog
quinin
anoth
antimalari
drug
activ
merscov
sarscov
belong
model
list
essenti
medicin
mefloquin
known
penetr
bloodbrain
barrier
found
inhibit
jc
viru
infect
replic
concentr
gener
achiev
brain
patient
given
mefloquin
malaria
lead
clinic
evalu
drug
treatment
progress
multifoc
leukoencephalopathi
fda
ad
box
warn
us
label
mefloquin
regard
potenti
neuropsychiatr
side
effect
addit
investig
warrant
determin
amodiaquin
mefloquin
valu
repurpos
treatment
mer
sar
cyclophilin
ubiquit
host
protein
believ
multipl
role
traffick
protein
fold
cell
activ
cyclosporin
cysa
form
complex
cyclophilin
therebi
block
cell
activ
cysa
licens
use
organ
transplant
suppress
immun
respons
cysa
also
shown
inhibit
coronavirus
includ
sarscov
merscov
effect
cell
cultur
howev
mechan
yet
determin
increas
evid
cyclophilin
involv
viral
replic
rna
virus
hepat
c
viru
hcv
west
nile
viru
may
also
appli
coronavirus
although
immunosuppress
properti
cysa
consid
risk
treat
viral
infect
patient
nonimmunosuppress
analog
cysa
bind
cyclophilin
higher
affin
develop
clinic
trial
hcv
therapeut
interferon
ifn
approv
fda
indic
hepat
c
although
reduc
sarscov
replic
mice
nhp
efficaci
treatment
sar
patient
mix
see
sect
vitro
studi
anoth
type
interferon
may
effect
either
alon
combin
combin
synergist
sarscov
vitro
regard
mer
vitro
vivo
preclin
studi
indic
alon
combin
ribavirin
may
therapeut
effect
given
earli
diseas
clinic
trial
howev
given
combin
treatment
lead
signific
benefit
patient
see
sect
iuml
superior
activ
merscov
infect
vitro
compar
ifn
valu
iuml
respect
current
evalu
merscov
random
clinic
trial
combin
lopinavirritonavir
investig
subtyp
combin
antivir
may
worthwhil
potenti
synergist
combin
could
reduc
effect
drug
dosag
ifnassoci
advers
effect
mani
cellular
process
regul
independ
chang
transcript
translat
kinasemedi
cell
signal
pathway
testament
biolog
import
kinas
kinas
identifi
along
gene
encod
protein
kinas
activ
april
kinas
inhibitor
grant
approv
us
fda
half
gain
approv
kinas
frequent
target
gene
class
cancer
therapi
second
g
proteincoupl
receptor
therapeut
target
therapeut
potenti
hosttarget
immunomodulatori
agent
viral
infect
receiv
consider
attent
recent
dyall
et
al
identifi
two
abelson
abl
kinas
inhibitor
imatinib
dasatinib
inhibit
merscov
sarscov
infect
cellscreen
assay
compound
significantli
inhibit
merscov
sarscov
micromolar
valu
low
cytotox
identifi
critic
merscov
sarscov
viru
entri
may
target
imatinib
inhibit
block
entri
virus
recent
system
kinom
analysi
investig
vitro
merscov
infect
suggest
erkmapk
kaktmtor
signal
pathway
specif
modul
infect
subsequ
analysi
licens
kinas
inhibitor
target
pathway
demonstr
kinas
inhibitor
target
erkmapk
signal
pathway
selumetinib
trametinib
inhibit
merscov
infect
ad
pre
postinfect
trametinib
demonstr
significantli
stronger
inhibitori
activ
merscov
selumetinib
suggest
specif
intermedi
erkmapk
signal
pathway
may
repres
crucial
foci
earli
viral
entri
late
viral
replic
event
viral
life
cycl
contrast
sorafenib
inhibitor
braf
compon
erkmapk
signal
pathway
vascular
endotheli
growth
factor
receptor
inhibit
merscov
infect
ad
cell
prior
infect
howev
inhibitori
activ
reduc
ad
postinfect
suggest
raf
kinas
primarili
involv
earli
viral
life
cycl
event
addit
inhibitori
activ
dabrafenib
raf
kinas
inhibitor
also
larg
ablat
ad
postinfect
miltefosin
alkyl
phospholipid
consid
inhibitor
protein
kinas
b
akt
garner
fda
approv
infecti
diseaserel
treatment
cutan
mucos
leishmaniasi
miltefosin
becam
directli
avail
us
center
diseas
control
prevent
treatment
freeliv
amoeba
infect
pretreat
cell
miltefosin
reduc
merscov
infect
effect
ad
postinfect
contrast
inhibit
mtor
sirolimu
everolimu
reduc
merscov
infect
ad
prior
pre
postinfect
suggest
critic
role
mtor
merscov
infect
recent
clinic
investig
wang
et
al
evalu
sirolimu
corticosteroid
addit
standard
antivir
treatment
random
control
trial
patient
sever
pneumonia
acut
respiratori
failur
importantli
addit
sirolimu
associ
improv
patient
outcom
includ
decreas
hypoxia
multiorgan
dysfunct
reduc
mean
time
liber
mechan
ventil
increas
clearanc
viru
thu
may
prudent
extend
studi
repurpos
kinas
inhibitor
beyond
standalon
therapeut
investig
also
consid
potenti
adjunct
therapi
numer
neurotransmitt
receptor
inhibitor
show
activ
merscov
sarscov
infect
drug
initi
develop
antipsychot
antihistamin
sed
five
neurotransmitt
receptor
antagonist
belong
chemic
class
phenothiazin
chlorpromazin
triflupromazin
thiethylperazin
promethazin
fluphenazin
phenothiazin
breakthrough
medic
develop
treat
mental
health
patient
reduc
episod
bizarr
behavior
hallucin
irrat
thought
although
phenothiazin
primarili
block
dopamin
receptor
also
anticholinerg
antihistamin
antiemet
effect
phenothiazin
chlorpromazin
triflupromazin
approv
antipsychot
chlorpromazin
use
offlabel
shortterm
treatment
nausea
migrain
triflupromazin
use
treat
sever
emesi
drug
seriou
side
effect
chlorpromazin
includ
akathisia
tardiv
dyskinesia
antivir
effect
chlorpromazin
extens
studi
drug
interfer
clathrinmedi
endocytosi
process
mani
virus
exploit
host
cell
entri
chlorpromazin
inhibit
entri
junin
viru
west
nile
viru
ebov
hcv
japanes
enceph
viru
suggest
broadspectrum
activ
could
exploit
earli
novel
viru
outbreak
chlorpromazin
may
similar
effect
coronavirus
drug
effect
inhibit
merscov
sarscov
human
coronaviru
express
green
fluoresc
protein
howev
timeofaddit
studi
indic
inhibitori
activ
merscov
retain
whether
ad
pre
postinfect
suggest
addit
effect
clathrinmedi
entri
impair
thiethylperazin
approv
antiemet
chlorpromazin
thiethylperazin
shown
inhibit
alphavirus
semliki
forest
viru
sfv
chikungunya
viru
chikv
drug
cross
brainblood
barrier
use
drug
could
benefici
treatment
chikv
includ
common
neurolog
complic
promethazin
antihistamin
use
sed
mani
countri
differ
brand
name
also
act
weak
antipsychot
activ
fluphenazin
common
antipsychot
use
treat
chronic
psychos
primarili
schizophrenia
belong
model
list
essenti
medicin
promethazin
fluphenazin
shown
vitro
activ
merscov
sarscov
may
valu
candid
repurpos
coronavir
infect
benztropin
mesyl
approv
anticholinerg
use
treat
parkinson
activ
merscov
sarscov
benztropin
also
identifi
screen
clinic
approv
drug
antivir
activ
hcv
ebov
although
detail
mechan
action
unknown
hcv
studi
indic
benztropin
inhibit
viru
entri
step
interf
viral
genom
replic
transcript
product
viral
progeni
viru
product
viral
progeni
argu
viru
entri
inhibitor
may
valu
decreas
incid
relaps
chronic
hcv
patient
receiv
liver
transplant
howev
peak
plasma
concentr
benztropin
may
low
effect
treat
acut
infect
benztropin
also
independ
identifi
two
drug
screen
ebov
antivir
recent
report
suggest
step
viru
attach
prior
viralcel
membran
fusion
target
benztropin
clomipramin
tricycl
antidepress
thiothixen
thioxanthen
antipsychot
also
shown
inhibit
merscov
sarscov
infect
vitro
addit
found
inhibit
evd
vlp
entri
approv
clinic
clomipramin
belong
model
list
essenti
medicin
sever
neurotransmitt
inhibitor
astemizol
promethazin
chlorphenoxamin
fluspirilen
activ
merscov
sarscov
cell
cultur
abl
find
report
activ
virus
astemizol
receptor
antagonist
treat
allerg
rhiniti
withdrawn
market
cardiac
advers
event
due
drug
overdos
report
extrem
rare
recent
astemizol
gain
renew
interest
anticanc
antimalari
drug
chlorphenoxamin
antihistamin
anticholinerg
current
preclin
trial
malaria
fluspirilen
approv
antipsychot
treatment
schizophrenia
known
autophagi
induc
autophagi
cellular
degrad
pathway
virus
exploit
propag
modul
autophagi
may
perturb
merscov
sarscov
infect
investig
broadspectrum
potenti
treatment
coronavir
infect
would
interest
sever
rnadna
synthesi
inhibitor
broadspectrum
activ
virus
includ
sarscov
merscov
inosin
monophosph
dehydrogenas
impdh
inhibitor
ribavirin
mycophenol
acid
mizoribin
inhibit
import
step
de
novo
synthesi
nucleic
acid
although
potenc
drug
virus
vari
ribavirin
use
combin
ifn
clinic
treatment
viral
infect
hepat
c
treatment
regimen
ribavirin
well
character
use
sar
mer
patient
mix
result
see
ribavirin
weakli
inhibit
merscov
vitro
conflict
data
report
activ
ribavirin
sarscov
mani
studi
ribavirin
perform
vero
cell
reportedli
defect
ribonucleosid
uptak
could
explain
lack
activ
ribavirin
cell
anoth
coronaviru
mous
hepat
viru
mhv
becom
sensit
ribavirin
exoriboucleas
activ
inactiv
presenc
exoribonucleas
ribavirin
inhibit
mhv
replic
mhv
exoribonucleas
suggest
function
proofread
viral
enzym
necessari
highfidel
replic
mhv
similarli
exoribonucleas
activ
merscov
sarscov
could
possibl
counteract
inhibitori
activ
ribavirin
mycophenol
acid
mpa
immunosuppress
use
prevent
organ
reject
broadspectrum
antivir
activ
antifung
antibacteri
anticanc
antipsoriat
properti
although
mpa
weak
inhibitori
activ
sarscov
vitro
promis
activ
merscov
potenti
altern
mpa
prodrug
mycophenol
mofetil
improv
oral
bioavail
mycophenol
mofetil
evalu
common
marmoset
model
mer
reduc
diseas
manifest
compar
observ
control
subject
howev
mer
marmoset
model
recapitul
human
diseas
due
rapid
onset
patholog
associ
exposur
method
mizoribin
approv
immunosuppress
organ
transplant
limit
advers
side
effect
shown
vitro
activ
hcv
bovin
viral
diarrhea
viru
bvdv
consid
altern
ribavirinifn
combin
treatment
hcv
infect
vivo
analysi
ribavirin
impdh
inhibitor
sarscovinfect
mice
suggest
agent
would
limit
benefit
chemotherapeut
gemcitabin
shown
vitro
activ
merscov
sarscov
drug
anticanc
mechan
attribut
abil
inhibit
ribonucleotid
reductas
essenti
de
novo
pyrimidin
biosynthesi
gemcitabin
shown
suppress
influenza
viru
rna
transcript
replic
target
ribonucleotid
reductas
show
antiretrovir
activ
vivo
mous
model
murin
leukemia
viru
merscov
sarscov
requir
activ
envelop
glycoprotein
host
proteas
cell
entri
endosom
nonendosom
pathway
inhibitor
host
cell
proteas
investig
possibl
antivir
serin
proteas
mediat
entri
via
nonendosom
pathway
merscov
sarscov
camostat
mesyl
use
treatment
chronic
pancreat
inhibit
glycoprotein
activ
merscov
sarscov
influenza
viru
cystein
proteas
inhibitor
clinic
develop
treat
parasit
infect
broadspectrum
activ
coronavirus
merscov
sarscov
filovirus
ebov
marburg
viru
paramyxovirus
nipah
viru
interestingli
zhou
et
al
demonstr
camostat
inhibitori
activ
sarscov
wherea
ebov
inhibit
suggest
differenti
host
proteas
requir
virus
inhibitor
endosom
cystein
proteas
current
phase
iii
trial
treatment
muscular
dystrophi
inhibit
merscov
sarscov
vitro
also
inhibit
filoviru
cell
entri
depend
virus
specif
serin
cystein
host
proteas
must
consid
select
proteas
inhibitor
antivir
therapeut
applic
therefor
increas
understand
relationship
host
proteas
viral
pathogenesi
determin
effect
treatment
option
viral
infect
lopinavir
identifi
inhibitor
merscov
sarscov
vitro
timeofaddit
experi
indic
drug
act
earli
stage
viral
entri
lopinavir
inhibitor
hiv
proteas
use
clinic
treatment
hiv
infect
given
combin
ritonavir
inhibitor
cytochrom
increas
blood
concentr
low
bioavail
lopinavir
lopinavir
also
inhibit
human
papilloma
viru
current
develop
topic
treatment
cervic
cancer
treatment
lopinavirritonavir
result
reduc
mortal
nhp
model
mer
lopinavir
shown
target
main
proteas
mpro
sarscov
howev
lopinavir
also
shown
act
intracellular
process
involv
coronaviru
replic
addit
studi
need
fulli
understand
mechan
action
lopinavir
involv
cellular
proteas
sar
outbreak
patient
open
clinic
trial
treat
lopinavirritonavir
combin
ribavirin
milder
diseas
cours
reduct
fatal
rate
compar
observ
histor
control
three
protein
synthesi
inhibitor
activ
coronavirus
identifi
emetin
anisomycin
omacetaxin
mepesuccin
emetin
natur
plant
alkaloid
anisomycin
antibiot
inhibit
protein
elong
identifi
antiprotozo
emetin
approv
amoebiasi
treatment
anisomycin
move
beyond
clinic
trial
dehydroemetin
synthet
emetin
deriv
fewer
side
effect
avail
investig
new
drug
anisomycin
origin
discov
peptidyl
transferas
inhibitor
also
activ
map
kinas
signal
pathway
addit
activ
merscov
sarscov
emetin
anisomycin
inhibit
anim
picornaviru
encephalomyocard
viru
anisomycin
vitro
activ
polioviru
omacetaxin
mepesuccin
plantderiv
alkaloid
anticanc
therapeut
receiv
fda
approv
treatment
chronic
myeloid
leukemia
omacetaxin
inhibit
merscov
bovin
coronaviru
human
enter
coronaviru
hepat
b
viru
spite
omacetaxin
broad
spectrum
anticoronaviru
activ
drug
activ
sarscov
drug
inhibit
coronavirus
target
protein
synthesi
may
potenti
develop
combin
therapi
drug
target
antivir
pathway
recent
investig
demonstr
potenti
estrogen
receptor
er
antagonist
repurpos
anticoronaviru
compound
exampl
toremifen
citrat
tamoxifen
citrat
activ
sarscov
merscov
develop
approv
anticanc
therapeut
drug
shown
activ
hcv
replic
vitro
mechanist
studi
reveal
er
function
associ
hcv
replic
er
promot
interact
hcv
replic
complex
hcv
polymeras
regul
hcv
genom
replic
abrog
tamoxifen
toremifen
tamoxifen
also
effect
inhibit
ebov
infect
vitro
howev
contrast
hcv
mechanist
studi
shown
toremifenemedi
ebov
inhibit
independ
er
pathway
toremifen
still
activ
ebov
cell
express
er
toremifen
act
late
step
viru
entri
intern
ebov
may
prevent
fusion
viral
endosom
membran
base
chemic
structur
toremifen
cation
amphiphil
drug
cad
known
lysosomotrop
could
affect
endosom
process
viru
entri
treatment
toremifen
led
surviv
mice
confirm
drug
effect
vivo
well
term
clinic
applic
toremifen
tamoxifen
good
bioavail
safeti
toler
profil
combin
long
histori
use
clinic
howev
prolong
qt
interv
note
toremifen
prescrib
patient
congenit
acquir
long
qt
syndrom
uncorrect
hypokalemia
uncorrect
hypomagnesemia
tamoxifen
increas
uterin
malign
stroke
pulmonari
embol
women
ductal
carcinoma
situ
high
risk
breast
cancer
despit
side
effect
drug
may
substanti
valu
shortterm
treatment
acut
coronavir
infect
advanc
patient
studi
care
evalu
pharmacokinet
profil
may
facilit
dose
strategi
limit
risk
advers
event
two
sterol
synthesi
inhibitor
terconazol
triparanol
shown
activ
merscov
sarscov
studi
viruslik
particl
vlp
demonstr
terconazol
inhibit
coronaviru
cell
entri
includ
merscov
sarscov
sterol
synthesi
pathway
shown
requir
infect
sever
virus
includ
hcv
terconazol
approv
vagin
yeast
infect
administ
oral
topic
suppositori
triparanol
approv
lower
plasma
cholesterol
withdrawn
due
numer
side
effect
cad
induc
accumul
cholesterol
late
endosom
shown
inhibit
ebov
entri
addit
drug
repurpos
develop
novel
antivir
countermeasur
need
emerg
coronavirus
end
design
develop
strategi
target
viral
replic
cycl
host
pathway
essenti
viral
replic
tabl
two
nucleosid
inhibitor
viral
rnadepend
rna
polymeras
potenti
broadspectrum
antivir
drug
activ
merscov
sarscov
cell
cultur
vivo
efficaci
remain
investig
addit
new
class
nucleosid
flexibl
purin
base
anticoronavir
activ
optim
could
gener
potent
inhibitor
coronavir
polymeras
surfac
glycoprotein
sarscov
merscov
coronavirus
consist
two
domain
contain
receptorbind
domain
rbd
need
extracellular
bind
contain
fusion
peptid
need
membran
fusion
releas
endocytosi
sarscov
facilit
bind
rbd
angiotensin
convert
enzym
receptor
host
cell
membranebound
cathepsin
l
cleav
protein
reveal
fusion
protein
fuse
membran
releas
viral
rna
inhibitor
cathepsin
l
complex
fusion
peptid
could
suitabl
target
inhibit
sarscov
entri
result
recent
studi
identifi
inhibitor
viral
entri
viral
proteas
helicas
potent
inhibit
merscov
sarscov
proteas
papainlik
proteas
proteas
could
also
use
antivir
target
drug
develop
requir
cleav
nonstructur
protein
viral
matur
proteas
inhibitor
suicid
proteas
inhibitor
bind
target
irrevers
howev
revers
proteas
inhibitor
may
greater
potenti
less
toxic
better
toler
recent
studi
helicas
inhibitor
show
three
domain
target
ntermin
metal
bind
domain
hing
domain
ntphelicas
domain
potenti
develop
new
drug
direct
rna
interfer
rnai
present
power
approach
develop
novel
virusspecif
therapeut
base
gene
silenc
recent
studi
shown
small
interf
rna
sirna
short
hairpin
rna
inhibit
express
viral
gene
therebi
block
replic
sarscov
cultur
cell
intranas
deliveri
combin
small
interf
rna
target
sarscov
open
read
frame
protein
decreas
sar
pathogenesi
nhp
potenti
rnai
candid
identifi
comput
model
merscov
requir
vitro
preclin
investig
sever
rnai
therapeut
treatment
viral
infect
enter
clinic
trial
includ
tkmebola
sirnalipid
nanoparticl
platform
target
ebov
technolog
great
potenti
therapeut
emerg
virus
viral
genom
sequenc
complet
short
time
frame
crucial
situat
epidem
novel
emerg
viral
infect
unfold
main
obstacl
rnai
strategi
lie
identif
suitabl
viral
target
deliveri
effici
nucleic
acid
target
cell
vivo
peptid
share
common
physicochem
properti
cad
facilit
interact
cell
membran
interfer
fusion
cellular
viral
membran
viru
entri
research
make
progress
defin
mechan
action
peptid
entri
inhibitor
envelop
virus
enfuvirtid
approv
hiv
inhibitor
enfuvirtid
peptid
deriv
amphipath
loopchelix
heptad
repeat
domain
hiv
ration
approach
base
scan
fusion
protein
sequenc
amphipath
sequenc
led
discoveri
addit
peptid
inhibitor
virus
includ
merscov
sarscov
chemic
modif
peptid
increas
vivo
stabil
bioavail
improv
potenti
clinic
applic
novel
broadspectrum
viral
entri
inhibitor
success
palivizumab
treatment
respiratori
syncyti
viru
infect
reinvigor
effort
develop
monoclon
antibodybas
therapeut
infecti
diseas
zmapp
monoclon
antibodi
cocktail
target
ebov
test
nhp
success
move
phase
ii
clinic
trial
human
evd
epidem
similarli
monoclon
antibodi
hendra
viru
administ
human
compassion
use
basi
exampl
demonstr
potenti
antibodi
therapi
combat
emergingreemerg
virus
similar
strategi
pursu
multipl
group
develop
antibodi
merscov
monoclon
antibodi
merscov
sourc
human
mice
librari
human
antibodi
librari
antibodi
target
rbd
subunit
demonstr
efficaci
anim
model
review
ying
et
al
monoclon
antibodi
therapi
impart
select
pressur
gener
resist
virus
although
mutant
escap
monoclon
antibodi
pressur
tend
less
fit
analysi
emerg
mutat
confer
resist
monoclon
antibodi
need
perform
altern
monoclon
antibodi
therapi
polyclon
antibodi
therapi
use
convalesc
sera
sera
sourc
nonhuman
human
anim
polyclon
antibodi
provid
advantag
monoclon
antibodi
escap
mutant
less
like
emerg
convalesc
sera
recommend
mer
phase
ii
intervent
clinic
trial
ongo
determin
efficaci
howev
avail
suitabl
donor
subject
present
signific
complic
approach
nonhuman
anim
sera
consid
safeti
concern
limit
option
fraction
nonhuman
sera
altern
howev
antibodymedi
clearanc
limit
due
failur
human
fc
receptor
recogn
antibodi
heavi
chain
altern
despeci
antibodi
use
fab
antibodi
fragment
howev
cost
suffici
materi
may
make
mass
product
fab
fragment
difficult
use
sera
human
mice
small
laboratori
anim
complic
sampl
acquisitionvolum
restraint
larger
laboratori
anim
may
provid
potenti
altern
sab
biotherapeut
develop
transchromosom
bovin
platform
gener
human
igg
antibodi
vaccin
transchromosom
cattl
protein
nanoparticl
inactiv
whole
viru
gener
fulli
human
polyclon
antibodi
demonstr
efficaci
murin
model
mer
despit
extens
effort
past
year
therapeut
prophylact
hiv
vaccin
remain
elus
antivir
agent
avail
treatment
aid
antivir
belong
differ
drug
class
target
differ
stage
viral
replic
avail
eg
revers
transcriptas
proteas
fusion
entri
integras
combin
treatment
drug
effect
result
sustain
virolog
respons
two
aspect
found
import
avoid
resist
select
drug
least
two
differ
target
select
drug
belong
differ
chemic
class
consider
may
also
appli
drug
combin
synergist
effect
mer
sarscov
broadspectrum
antivir
therapi
great
valu
treat
emerg
infect
take
time
develop
directact
antivir
treatment
chronic
hepat
c
clinician
depend
ifn
ribavirin
number
year
eventu
ifn
ribavirin
combin
replac
effect
fixedcombin
therapi
use
directact
antivir
target
multipl
step
hcv
life
cycl
ifn
ribavirin
contribut
significantli
treatment
viral
infect
directact
antivir
exist
howev
major
side
effect
option
broadspectrum
antivir
improv
safeti
profil
would
benefici
use
emerg
coronaviru
infect
influenza
virus
character
high
mutat
rate
rna
genom
avail
vaccin
may
protect
novel
pandem
strain
antivir
agent
consid
essenti
compon
prepared
combin
directact
antivir
evalu
addit
synergist
effect
prevent
resist
one
tripl
combin
oseltamivir
amantadin
ribavirin
synergist
prevent
resist
vivo
highlight
potenti
combinatori
therapi
recent
epidem
evd
western
africa
renew
urgenc
develop
treatment
emerg
virus
although
vaccin
directact
antivir
treatment
investig
none
approv
clinic
use
priorit
panel
drug
approv
indic
consid
repurpos
fda
emerg
use
author
two
drug
also
activ
merscov
sarscov
amodiaquin
antimalari
agent
toremifen
citrat
breast
cancer
treatment
addit
broadspectrum
antivir
agent
includ
repurpos
drug
top
prioriti
futur
emerg
infect
includ
coronaviru
infect
panel
broadspectrum
drug
care
valid
efficaci
safeti
could
use
combin
would
suppli
minimum
protect
patient
healthcar
worker
outbreak
locat
panel
drug
could
use
situat
known
reemerg
pathogen
specif
antivir
agent
vaccin
approv
unknown
novel
pathogen
could
aris
effect
develop
countermeasur
depend
develop
appropri
anim
model
uniformli
recapitul
human
diseas
progress
sever
patholog
manifest
anim
model
human
diseas
one
anim
model
fulli
reflect
sar
mer
therefor
research
face
explor
sever
small
anim
model
choos
bestfit
model
date
anim
model
fulli
recapitul
human
diseas
thu
anim
model
mer
sar
need
refin
mani
small
anim
model
evalu
potenti
mer
sar
model
includ
mice
hamster
ferret
mer
syrian
hamster
guinea
pig
sar
four
murin
model
report
mer
first
model
demonstr
promis
involv
transduct
respiratori
tract
put
merscov
receptor
human
major
indic
diseas
model
viral
load
lung
day
postinocul
although
clinic
sign
diseas
includ
weight
loss
limit
model
use
pathogenesi
countermeasur
studi
lethal
dissemin
mer
infect
demonstr
transgen
mice
express
human
inflammatori
process
observ
brain
mice
contrast
human
diseas
cn
involv
report
transgen
mous
mer
model
develop
mous
gene
replac
human
gene
control
endogen
mous
promot
use
model
merscovinfect
mice
develop
lung
patholog
addit
administr
human
monoclon
antibodi
spike
protein
transgen
mice
provid
protect
merscov
infect
cluster
regularli
interspac
short
palindrom
repeatcrisprassoci
protein
gene
edit
technolog
use
modifi
mous
match
human
alter
amino
acid
posit
interestingli
wild
type
viru
infect
mice
result
improv
model
mer
howev
serial
passag
merscov
result
intranas
exposur
mice
led
weight
loss
sever
respiratori
diseas
includ
ardslik
sign
reduc
pulmonari
function
merscov
infect
rabbit
also
evalu
model
mer
haagman
et
al
demonstr
merscov
infect
rabbit
develop
obviou
clinic
sign
infecti
viru
could
detect
upper
respiratori
tract
furthermor
epitheli
cell
bronchiol
termin
bronchiol
respiratori
tract
posit
merscov
immunohistochemistri
insitu
hybrid
reflect
tissu
tropism
human
diseas
use
rabbit
model
houser
et
al
demonstr
human
monoclon
antibodi
given
preexposur
reduc
viral
rna
lung
titer
day
postexposur
given
postexposur
due
phylogenet
similar
human
nhp
model
diseas
long
consid
necessari
evalu
countermeasur
infecti
diseas
rhesu
monkey
common
marmoset
evalu
potenti
model
mer
follow
intratrach
instil
merscov
rhesu
monkey
model
lung
patholog
observ
experi
use
rhesu
monkey
indic
develop
limit
system
diseas
transient
respiratori
diseas
radiolog
evalu
indic
inflammatori
infiltr
develop
shortli
exposur
analysi
lung
tissu
revers
transcriptas
quantit
polymeras
chain
reaction
indic
viru
replic
lung
similar
mer
african
green
monkey
agm
rhesu
monkey
cynomolgu
monkey
common
marmoset
identifi
potenti
model
sar
smit
et
al
compar
sar
cov
infect
young
agm
cynomolgu
monkey
observ
neither
speci
develop
clinic
sign
experi
gross
patholog
indic
multifoc
pulmonari
consolid
consolid
greyr
firm
lung
lesion
affect
lung
one
subject
comparison
cynomolgu
monkey
develop
small
patchi
macroscop
lesion
similar
merscov
infect
nhp
viral
load
decreas
exposur
day
day
comparison
agm
rhesu
monkey
cynomolgu
monkey
support
agm
best
avail
nhp
model
sar
agm
develop
highest
viral
load
diseas
compar
cynomolgu
rhesu
monkey
lethal
diseas
observ
speci
therefor
develop
sar
model
warrant
sinc
lethal
respiratori
tract
diseas
hallmark
sar
altern
old
world
nhp
mani
group
employ
marmoset
model
human
infecti
diseas
common
marmoset
evalu
mer
model
studi
demonstr
common
marmoset
develop
diseas
follow
exposur
merscov
shown
histopatholog
analysi
radiolog
analysi
rtqpcr
howev
variabl
result
report
exposur
methodolog
impact
diseas
progress
therefor
mockinfect
group
must
includ
account
patholog
artifact
virusspecif
patholog
could
quantifi
use
comput
tomographi
futur
experi
use
larg
group
size
could
use
countermeasur
evalu
greenough
et
al
perform
serial
euthanasia
studi
sarscov
infect
marmoset
subject
intratrach
expos
sarscov
observ
mild
inconsist
clinic
sign
diseas
viral
load
peak
day
postinfect
histopatholog
indic
interstiti
pneumon
multinucl
syncytia
describ
mild
observ
late
timepoint
subject
overal
research
need
develop
anim
model
sar
reflect
human
diseas
present
drug
repurpos
potenti
discuss
tabl
advantag
easi
access
avail
decreas
cost
develop
provid
wide
array
option
combin
studi
pharmacolog
knowledg
avail
compound
may
also
reduc
concern
regard
advers
effect
patient
gener
translat
databas
encompass
pharmacodynam
data
infecti
diseas
biolog
data
propos
would
greatli
facilit
decis
make
pursu
new
drug
combin
mani
drug
potenti
broadspectrum
antivir
activ
alreadi
clinic
use
treat
viral
infect
novel
drug
develop
move
preclin
clinic
phase
also
becom
avail
combin
therapi
care
taken
pharmacolog
evalu
combin
avoid
possibl
contraind
drug
regard
diseas
advers
effect
novel
broadspectrum
replic
inhibitor
gilead
scienc
phase
clinic
trial
immunomodul
nitazoxanid
steroid
statin
along
directact
antivir
agent
coronavirus
develop
repres
interest
partner
combin
combin
involv
broadspectrum
versu
specif
antivir
agent
drug
differ
mechan
action
drug
target
differ
step
viral
life
cycl
identifi
one
potent
combin
activ
anim
model
would
greatli
increas
prepared
next
coronaviru
outbreak
elucid
crystal
structur
viral
protein
led
novel
approach
ration
drug
design
ration
design
investig
use
protein
structur
inform
silico
screen
affin
activ
site
viral
protein
hold
promis
proteas
inhibitor
one
big
success
ration
drug
design
year
public
proteas
structur
saquinavir
develop
record
time
bench
bedsid
licens
use
aid
total
six
antivir
proteas
design
approv
similarli
hcv
approach
base
known
crystal
structur
viral
protein
success
guid
design
synthesi
inhibitor
hcv
proteas
peptidomimet
telaprevir
boceprivir
due
power
comput
model
use
crystal
structur
known
coronavirus
crystal
structur
viral
proteas
mpro
plpro
sarscov
merscov
determin
rel
quickli
structur
alreadi
use
discoveri
inhibitor
high
bind
affin
activ
site
proteas
structur
addit
merscov
sarscov
viral
protein
yet
determin
would
offer
addit
viral
target
drug
discoveri
structur
design
help
develop
inhibitor
prepar
futur
outbreak
yet
unknown
emerg
coronavirus
base
potenti
zoonot
transmiss
coronavirus
bat
human
crystal
structur
main
proteas
mpro
differ
bat
coronaviru
famili
propos
screen
identifi
broadspectrum
antivir
agent
proofofprincipl
shown
novel
proteas
inhibitor
inhibit
bat
coronaviru
quickli
identifi
inhibitor
merscov
silico
dock
studi
mpro
merscov
bat
coronaviru
sever
drug
eg
toremifen
citrat
terconazol
fig
belong
group
compound
term
cation
amphiphil
drug
cad
phenothiazin
eg
fluphenazin
chlorpromazin
fig
cad
shown
inhibit
hcv
entri
virushost
cell
fusion
intercal
cholesterolrich
domain
host
cell
membran
increas
membran
fluiditi
drug
act
mechan
may
present
interest
new
class
broadspectrum
antivir
cad
known
lysomotrop
accumul
acid
compart
tertiari
amin
group
proton
compound
act
mild
base
neutral
low
ph
acid
environ
endolysosom
cad
intercal
membran
alter
biophys
properti
membran
therebi
could
potenti
interfer
fusion
viru
endolysosom
membran
concept
interf
viru
entri
bud
physicochem
properti
drug
intrigu
mani
virus
would
suscept
type
inhibit
cad
could
use
broadspectrum
antivir
agent
detail
structureact
relationship
studi
cad
requir
determin
chemic
core
structur
physicochem
properti
import
type
antivir
agent
futur
investig
regard
conserv
mechan
action
coronavirus
well
emerg
virus
warrant
approv
drug
activ
merscov
sarscov
could
use
lead
compound
antivir
drug
develop
pharmaceut
usual
undergon
multipl
round
structureact
relationship
studi
gener
analog
improv
drug
activ
origin
indic
target
analog
drug
activ
merscov
sarscov
may
still
avail
could
screen
identifi
analog
increas
antivir
activ
although
drug
analog
would
go
full
licensur
process
would
littl
ad
initi
cost
associ
produc
structureact
relationship
compound
recycl
old
analog
one
approach
may
valu
develop
novel
drug
viral
infect
streamlin
process
need
develop
effect
treatment
measur
emerg
reemerg
pathogen
avail
panel
approv
broadspectrum
drug
would
clearli
benefici
could
use
treat
diseas
symptom
reduc
morbid
specif
act
antivir
vaccin
develop
larg
number
potenti
drug
therapeut
treatment
mer
sar
discuss
greatest
challeng
best
downselect
evalu
differ
approach
learn
drug
develop
aid
hepat
allevi
diseas
symptom
increas
life
span
may
achiev
goal
rather
look
treatment
provid
complet
recoveri
broadspectrum
antivir
specif
antivir
immun
modul
import
role
treat
viral
infect
either
individu
combin
effect
commun
differ
institut
partner
govern
industri
academ
nation
intern
partner
essenti
combin
drug
discoveri
effort
increas
chanc
one
potenti
therapeut
agent
advanc
develop
stage
time
anoth
outbreak
emerg
coronaviru
occur
